// App-Quantinova.ai

69 : Does Low Disease Activity at Six Months Predict Remission at 12 Months in Rheumatoid Arthritis Patients Treated with Biologics in a RealWorld Setting?

Researchers

Presenter

  • Philip Baer

Principal Investigators

  • William G. Bensen

  • Andrew Chow

  • Rafat Y. Faraawi

  • Denis Choquette

  • Isabelle Fortin

  • John T. Kelsall

  • Dalton E. Sholter

  • Emmanouil Rampakakis

  • John S. Sampalis

  • Francois Nantel

  • Allen J. Lehman

  • May Shawi

  • Susan M. Otawa

Medical Centers

  • Scarborough,Canada

  • Street Medical Group, Edmonton,Canada

  • St. Josephs Hospital, McMaster University, Hamilton, ON, Canada

  • Centre de sante et de services sociaux de Rimousk, Rimouski,Canada

  • Credit Valley Rheumatology, University of Toronto, McMaster University, Mississauga,Canada

  • Institut de Rhumatologie, Montreal, QC, Canada

  • Mary Pack Arthritis Center and St Paul's Hospital, Division of Rheumatology, University of British Columbia, Vancouver,Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab

  • golimumab

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved